TG Therapeutics Inc. [NASDAQ: TGTX] traded at a low on 01/14/21, posting a -3.58 loss after which it closed the day’ session at $51.19. The company report on January 8, 2021 that TG Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference.
Presentation scheduled for Tuesday, January 12, 2021 at 2:00 PM ET.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
TG Therapeutics, Inc. (NASDAQ: TGTX) announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference, being held virtually. The presentation is scheduled to take place on Tuesday, January 12, 2021 at 2:00 PM ET.
The results of the trading session contributed to over 1603063 shares changing hands. Over the past one week, the price volatility of TG Therapeutics Inc. stands at 5.56% while the volatility over the past one month is 5.78%.
The market cap for TGTX stock reached $6.93 billion, with 119.18 million shares outstanding and 104.22 million shares in the current float. Compared to the average trading volume of 1.99M shares, TGTX reached a trading volume of 1603063 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about TG Therapeutics Inc. [TGTX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TGTX shares is $63.57 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TGTX stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for TG Therapeutics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on September 01, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $32 to $38. The new note on the price target was released on August 11, 2020, representing the official price target for TG Therapeutics Inc. stock. Previously, the target price had yet another raise to $60, while Evercore ISI analysts kept a Outperform rating on TGTX stock. On January 17, 2020, analysts increased their price target for TGTX shares from 20 to 24.
The Average True Range (ATR) for TG Therapeutics Inc. is set at 3.15, with the Price to Sales ratio for TGTX stock in the period of the last 12 months amounting to 34658.19. The Price to Book ratio for the last quarter was 35.80, with the Price to Cash per share for the same quarter was set at 1.88.
How has TGTX stock performed recently?
TG Therapeutics Inc. [TGTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.66. With this latest performance, TGTX shares gained by 17.01% in over the last four-week period, additionally plugging by 130.48% over the last 6 months – not to mention a rise of 263.05% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TGTX stock in for the last two-week period is set at 59.74, with the RSI for the last a single of trading hit 51.68, and the three-weeks RSI is set at 63.26 for TG Therapeutics Inc. [TGTX]. The present Moving Average for the last 50 days of trading for this stock 39.71, while it was recorded at 52.65 for the last single week of trading, and 25.60 for the last 200 days.
TG Therapeutics Inc. [TGTX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and TG Therapeutics Inc. [TGTX] shares currently have an operating margin of -112009.87. TG Therapeutics Inc.’s Net Margin is presently recorded at -113730.92.
Return on Total Capital for TGTX is now -328.32, given the latest momentum, and Return on Invested Capital for the company is -339.50. Return on Equity for this stock declined to -551.85, with Return on Assets sitting at -140.19. When it comes to the capital structure of this company, TG Therapeutics Inc. [TGTX] has a Total Debt to Total Equity ratio set at 106.16. Additionally, TGTX Total Debt to Total Capital is recorded at 51.49, with Total Debt to Total Assets ending up at 25.15. Long-Term Debt to Equity for the company is recorded at 101.48, with the Long-Term Debt to Total Capital now at 49.23.
Reflecting on the efficiency of the workforce at the company, TG Therapeutics Inc. [TGTX] managed to generate an average of -$1,290,082 per employee. Receivables Turnover for the company is 3.20 with a Total Asset Turnover recorded at a value of 0.00.TG Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.40 and a Current Ratio set at 3.40.
Earnings analysis for TG Therapeutics Inc. [TGTX]
With the latest financial reports released by the company, TG Therapeutics Inc. posted -0.44/share EPS, while the average EPS was predicted by analysts to be reported at -0.46/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 4.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TGTX.
Insider trade positions for TG Therapeutics Inc. [TGTX]
There are presently around $4,426 million, or 67.30% of TGTX stock, in the hands of institutional investors. The top three institutional holders of TGTX stocks are: FMR LLC with ownership of 10,961,505, which is approximately -13.37% of the company’s market cap and around 10.20% of the total institutional ownership; RA CAPITAL MANAGEMENT, L.P., holding 8,825,849 shares of the stock with an approximate value of $451.8 million in TGTX stocks shares; and BLACKROCK INC., currently with $393.38 million in TGTX stock with ownership of nearly 8.476% of the company’s market capitalization.
Positions in TG Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 112 institutional holders increased their position in TG Therapeutics Inc. [NASDAQ:TGTX] by around 20,218,561 shares. Additionally, 75 investors decreased positions by around 17,723,515 shares, while 25 investors held positions by with 48,527,098 shares. The mentioned changes placed institutional holdings at 86,469,174 shares, according to the latest SEC report filing. TGTX stock had 36 new institutional investments in for a total of 5,589,728 shares, while 26 institutional investors sold positions of 2,562,134 shares during the same period.